A Path Forward for Contrave?

September 21st, 2011 by MorganDowney Leave a reply »

Orexigen Therapeutics has announced that, following a meeting with the FDA, it has reached an agreement on a cardiovascular outcomes trial. If the trial meets agreed upon endpoints, it will be approved by the FDA. While the FDA will still convene an Advisory Committee meeting in 2012 to discuss cardiovascular outcomes for obesity drugs, that discussion will not affect the agreement with Orexigen.  See their press release. Orexigen Therapeutics, Inc. – Press Release This is exciting news, indicating a possible path forward for their product, Contrave.